Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | UBE2N | P61088 | 1/20 | 0.73 |
| ▸ | HTR6 | P50406 | 9/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542068 | 1.00 | KDM4E (0.73) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL29072262 | 0.88 | KDM4E (0.76) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL946340 | 0.86 | KDM4E (0.77) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL30542061 | 0.86 | KDM4E (0.77) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL29576861 | 0.86 | KDM4E (0.81) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL723339 | 0.86 | KDM4E (0.81) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL29072217 | 0.85 | KDM4E (0.67) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL29694480 | 0.85 | KDM4E (1.00) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL946372 | 0.85 | KDM4E (1.00) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL946492 | 0.83 | KDM4E (0.77) | KDM4EUBE2NHTR6CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693503-A | Quinolinone derivative containing sulfonyl substituted indolyl acylhydrazone structure on 1-position nitrogen atom, and preparation method and application thereof | 太原理工大学 | 2023-09-05 | — | — | CN | claimed |
| CN-103391936-B | Carcinostatic agent | THE UNIVERSITY OF TOKYO (JP) | 2016-04-27 | — | — | CN | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | KDM4E 540/4885UBE2N 2544/4885HTR6 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.